LAV leads $50m Series B funding in Chinese drug maker Link Pharma

LAV leads $50m Series B funding in Chinese drug maker Link Pharma

Photo: Pixabay

Clinical stage drug maker Lynk Pharmaceuticals Co. has completed a Series B round of financing, raising as much as $50 million, led by the Shanghai-based venture capital firm Lilly Asia Ventures (LAV), the investor announced on Friday.